Comparison Between Plasma Levels of β-Thromboglobulin and Platelet Factor 4 in Various Diseases

1979 ◽  
Author(s):  
T. Matsuda ◽  
T. Seki ◽  
M. Ogawara ◽  
R. Miura ◽  
M. Yokouchi ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Normal Subjects ◽  
Platelet Factor 4 ◽  
Transient Ischemic Attacks ◽  
Platelet Factor ◽  
Mean Values ◽  
Vein Thrombosis ◽  
Normal Limits ◽  
Acute Deep Vein Thrombosis ◽  
Deep Vein

Contentrations of β-thromboglobulin (β-TG) and platelet factor 4 (PF-4) in platelet poor plasma were determined using radioimmunoassay in 97 healthy subjects and 307 hospitalized patients. In normal subjects, mean values (and SEM) of β-TG and PF-4 were 37±2 ng/ml and 8.3+1.5 ng/ml, respectively. Levels of β-TG increased with age. A statistically significant correlation between concentrations of β-TG and PF-4 was observed in 30 normal subjects (r=0.77, p<0.001). Levels of these protein increased in cases of DIC, acute deep vein thrombosis, acute myocardial infarction, acute cerebral infarction, transient ischemic attacks, diabetes mellitus with retinopathy or nephrotic syndrome, whereas these decreased in patients with aplastic anemia or acute leukemia. In a case of DIC with suppressed production of platelets in bone marrow, concentrations of β-TG and PF-4 remained within normal limits. There were few cases, in whom discrepancies between levels of β-TG and PF-4 were observed. Following oral administration of dipyridamole (300 mg daily), concentrations of β-TG and PF-4 decreased. From these results, it is concluded that elevation of β-TG ot PF-4 indicates hypercoagulable states.

Acute Deep Vein Thrombosis Treated with Porcine Plasmin

1974 ◽  
Vol 32 (02/03) ◽  
pp. 468-482 ◽  
Author(s):  
O Storm ◽  
P Ollendorff ◽  
E Drewsen ◽  
P Tang
Keyword(s):  
Deep Vein Thrombosis ◽  
Lower Limb ◽  
Initial Dose ◽  
Treated Group ◽  
Allergic Reactions ◽  
Double Blind ◽  
Vein Thrombosis ◽  
Thrombolytic Effect ◽  
Acute Deep Vein Thrombosis ◽  
Deep Vein

SummaryThe thrombolytic effect of pig plasmin was tested in a double blind trial on patients with deep venous thrombosis in the lower limb. Only patients with not more than three days old thrombi were selected for this study. The diagnosis of deep vein thrombosis was made clinically and confirmed by phlebography. Lysofibrin Novo (porcine plasmin) or placebo (porcine plasminogen) was administered intravenously to the patients. The enzyme and the placebo were delivered as lyophilized powder in labelled bottles - the contents of the bottles were unknown to the doctor in charge of the clinical administration of the trial. An initial dose of plasmin/plasminogen of 30 unit per kg body weight given slowly intravenously (1-1% hours infusion) was followed by a maintenance dosis of 15 per cent the initial dose per hour for the following 5-7 hours. In most cases a similar maintenance dosis was given the next day. In all patients heparin was administered after ending the plasmin/plasminogen infusion. The results of the treatment was evaluated clinically as well as by control phlebo- grams the following days.A statistically significant improvement was found in the plasmin treated group compared with the placebo (plasminogen) treated group. Thrombolysis was obtained clinically and phlebographically in 65 per cent of the plasmin treated group, but only in 15 per cent of the control patients were improvements found.This study has thus demonstrated that plasmin treatment according to a standard scheme was able to induce thrombolysis. There were only a few and insignificant side effects. Allergic reactions have not been seen and only very simple tests are required.

Subcutaneous Recombinant Hirudin (HBW 023) Versus Intravenous Sodium Heparin in Treatment of Established Acute Deep Vein Thrombosis of the Legs: a Multicentre Prospective Dose-ranging Randomized Trial

1997 ◽  
Vol 77 (05) ◽  
pp. 0834-0838 ◽  
Author(s):  
François Schiele ◽  
Folke Lindgaerde ◽  
Henry Eriksson ◽  
Jean-Pierre Bassand ◽  
Anders Wallmark ◽  
...  
Keyword(s):  
Bleeding Complications ◽  
Recombinant Hirudin ◽  
Serious Adverse Events ◽  
Sodium Heparin ◽  
Efficacy Analysis ◽  
Vein Thrombosis ◽  
Dose Ranging ◽  
Acute Deep Vein Thrombosis ◽  
Deep Vein ◽  
Intravenous Sodium

SummaryThe aim of this multicentre, prospective, randomised, dose-ranging study was to compare the safety and efficacy of subcutaneous recombinant hirudin (HBW 023) against intravenous sodium heparin in acute lower limb deep venous thrombosis (DVT). Patients were randomized to treatment with either HBW 023 or heparin for 5 ±1 days. HBW 023 was given according to body-weight in three dose groups. Thromboembolic disease was assessed by phlebography and ventilation/perfusion (V/Q) scanning on Bay 1 and Day 5±1. One hundred and fifty-five patients were enrolled, of these 121 were evaluable for efficacy analysis. Significantly fewer patients on HBW 023 developed new V/Q abnormalities during the treatment period, (p = 0.006). There was no difference between the groups in thrombus extension or regression, major bleeding complications or serious adverse events. There were significantly fewer findings of new V/Q mismatch after treatment with HBW 023, and anticoagulant control was superior in these patients.

scholarly journals The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis—A Two-Year Prospective Study

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 901
Author(s):  
Katja Perdan-Pirkmajer ◽  
Polona Žigon ◽  
Anja Boc ◽  
Eva Podovšovnik ◽  
Saša Čučnik ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Prospective Study ◽  
Anticoagulant Therapy ◽  
Predictive Value ◽  
Anticoagulation Therapy ◽  
Time Frame ◽  
Vein Thrombosis ◽  
Therapeutic Decisions ◽  
Acute Deep Vein Thrombosis ◽  
Deep Vein

Antiphospholipid syndrome (APS) is an important cause of deep vein thrombosis (DVT). According to current APS classification criteria, APS cannot be confirmed until 24 weeks after DVT. This time frame results in frequent discontinuation of anticoagulant treatment before APS is diagnosed. Therefore, the aim of our study was to evaluate the potential predictive value of anticardiolipin (aCL) and anti-β2glycoprotein I (anti-β2GPI) before discontinuation of anticoagulation therapy. Patients with newly diagnosed DVT were included into a 24-month prospective study. All patients received anticoagulant therapy. aCL and anti-β2GPI were determined at inclusion and every four weeks for the first 24 weeks and then one and two years after inclusion. APS was confirmed in 24/221 (10.9%) patients. At the time of acute DVT 20/24 (83.3%), APS patients had positive aCL and/or anti-β2GPI. Two patients had low aCL levels and two were negative at the time of acute DVT but later met APS criteria due to lupus anticoagulant (LA). Our data indicate that negative aCL and/or anti-β2GPI at the time of acute DVT make further aPL testing unnecessary; however, LA should be determined after discontinuation of anticoagulant therapy. Positive aCL and/or anti-β2GPI at the time of acute DVT have a strong positive predictive value for APS and may support therapeutic decisions.

Thromboaspiration device in the treatment of acute deep vein thrombosis and pulmonary embolism

2018 ◽  
Vol 25 (2) ◽  
Author(s):  
Carlo Setacci ◽  
Marco Tadiello ◽  
Francesco Setacci ◽  
Gianmarco De Donato ◽  
Matteo Tozzi ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Vein Thrombosis ◽  
Acute Deep Vein Thrombosis ◽  
Deep Vein
Sign in / Sign up

Export Citation Format

Share Document